Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended December 31, 1995, and the six-month period ended December 31, 1995, for LecTec Corporation (Note: The request metadata lists "Axogen, Inc.", but the filing text explicitly identifies the registrant as LecTec Corporation). The company operates in the medical products sector, with primary product groups including conductive products, medical tapes, and therapeutic products. The financial statements are unaudited.
Key Financial Metrics
| Metric | Q2 1996 (3 Months) | Q2 1995 (3 Months) | YTD 1996 (6 Months) | YTD 1995 (6 Months) |
|---|---|---|---|---|
| Total Revenues | $3,255,110 | $3,685,809 | $6,717,561 | $6,590,332 |
| Gross Profit | $1,297,653 | $1,305,547 | $2,636,857 | $2,652,856 |
| Gross Margin % | 39.9% | 35.4% | 39.3% | 40.3% |
| Operating Profit (Loss) | ($673,915) | $9,516 | ($787,234) | $90,509 |
| Net Earnings (Loss) | ($663,787) | $39,331 | ($759,153) | $118,267 |
| EPS (Basic/Diluted) | ($0.17) | $0.01 | ($0.20) | $0.03 |
| Cash and Equivalents | $491,633 | N/A | $491,633 | $824,638 |
| Working Capital | $3,422,665 | N/A | $3,422,665 | $4,490,796 |
| Current Ratio | 2.99 | N/A | 2.99 | 4.34 |
| Long-term Debt | $0 | $0 | $0 | $0 |
Material Changes vs. Prior Period
- Revenue Decline in Q2: Second-quarter revenues decreased 11.7% year-over-year. This was driven by a 50.4% drop in medical tape sales (due to the absence of a major converter order) and a 5.6% drop in therapeutic sales. These declines were partially offset by a 12.9% increase in conductive product sales.
- YTD Revenue Growth: For the six months ended December 31, 1995, revenues increased 1.9% year-over-year, driven by growth in conductive and therapeutic products.
- Significant Operating Loss: The company shifted from a slight operating profit in Q2 1995 ($9,516) to a significant operating loss in Q2 1996 ($673,915). This was primarily caused by a loss on the sale of direct marketing assets of the Natus subsidiary and increased operating expenses.
- Expense Increases: Selling, general, and administrative (SG&A) expenses surged to $1.47 million in Q2 1996 from $884,880 in Q2 1995 (45.1% of revenue vs. 24.0%). Research and development (R&D) expenses also rose to $503,518 from $411,151, driven by costs for a non-nicotine smoking cessation product and a pain patch program.
- Cash Flow: Net cash used in operating activities was $191,749 for the six months ended December 31, 1995, compared to $431,851 used in the prior year period. Investing activities used $290,361, primarily for property, plant, and equipment.
Guidance, Outlook, and Risks
- Capital Expenditures: Management estimates capital expenditures will approach $500,000 for fiscal 1996, anticipated to be financed by operations.
- Liquidity: The company maintains a $1,000,000 line of credit. While the current ratio decreased to 2.99 from 4.34, management describes the balance sheet as strong with no long-term debt.
- Key Risks and Contingencies:
- Natus Subsidiary Losses: The company recorded a loss related to the pending sale of direct marketing assets of its Natus subsidiary. Losses generated by Natus cannot currently be utilized by LecTec for tax benefits.
- Raw Material Costs: Increased raw material costs for all products negatively impacted gross margins year-to-date.
- Product Mix Volatility: Revenue is sensitive to large orders (e.g., the missing major tape converter order significantly impacted Q2 results).
- Unusual Items: A $300,000 loss on the disposal of assets was recorded in the cash flow statement adjustments, related to the Natus asset sale.
Investor Verification Checklist
- Verify the status and expected closing date of the sale of Natus Corporation's direct marketing assets.
- Confirm the timeline for the commercialization of the non-nicotine smoking cessation product and pain patch program to assess future R&D ROI.
- Monitor the recurrence of the major medical tape converter order to validate future revenue stability in that segment.
- Review the utilization of the $1,000,000 line of credit given the decrease in working capital and cash reserves.
- Assess the impact of rising raw material costs on future gross margin targets.